US FDA approves AstraZeneca’s Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma

November 02 2017 Accelerated approval of the selective Bruton tyrosine kinase (BTK) inhibitor in MCL marks AstraZeneca’s entry into the treatment of blood cancers80% of patients receiving Calquence achieved an overall response, with 40% achieving a complete responseAstraZeneca and its haematology research an... Read more